The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

摘要: Cyclooxygenase (COX)-2 inhibitors including celecoxib are as effective non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA) and have less gastrointestinal toxicity. Although they associated with higher costs, COX-2 may simultaneously reduce costs adverse events, hence, their overall economic benefit should be assessed. To evaluate incremental cost effectiveness ratio (ICER) versus ns-NSAIDs, with/without proton-pump inhibitor (PPI) co-therapy, for managing OA Saudi Arabian subjects aged ≥65 years. The National Institute Health Care Excellence health model from UK, updated relative risks events using CONDOR trial data, was adapted. Patients received or omeprazole. measure quality-adjusted life years (QALYs) gained per patient. analysis conducted patient’s perspective. Frequencies resource use were based on data collected July 2012 seven private hospitals Jeddah, Arabia. Probabilistic sensitivity performed to construct cost-effectiveness acceptability curves (CEACs). Over a 6-month duration, QALYs patient (0.37) plus PPI (0.40) comparators. Ibuprofen showed lowest expected (US$ 1,314.50 US$ 1,422.80 1,543.50 celecoxib). Celecoxib most cost-effective option an ICER 1,805.00, followed by (ICER, 7,633.33) ibuprofen PPI. 2- 5-year durations, PPI, celecoxib, gained/patient lower ICERs These <1 gross domestic product/capita Arabia 2013 25,961). CEACs over 6 months’ significantly likelihood that alone would more comparators once willingness pay is 2,000.00. After considering new event risks, co-therapy deemed very medium- long-term patients